drugset / Trial / NCT00606268

A Study of Safety and Pharmacokinetics of Repeated Dose of Micafungin as Antifungal Prophylaxis in Children and Adolescents Who Undergo Hematopoietic Stem Cell Transplant

NCT00606268

Phase 1 Completed 42 enrolled Astellas Pharma Inc
Non-randomizedParallel-groupOpen-labelPrevention

Summary

The study will evaluate PK and safety of two dose levels of Micafungin (FK463) as Antifungal prophylaxis in children and adolescents undergoing HSCT

Timeline

Start
2007-11
Primary completion
2009-03
Completion
2009-03

Drugs

EvaluationDrugModalityDoseRoute
Subject Micafungin Peptide 1 mg/kg
Subject Micafungin Peptide 1.5 mg/kg